{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T11:21:35Z","timestamp":1787656895252,"version":"build-2736575974"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T00:00:00Z","timestamp":1787616000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T00:00:00Z","timestamp":1787616000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004721","name":"The University of Tokyo","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004721","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    While immune effector cell-associated neurotoxicity syndrome (ICANS) remains one of the major adverse events in CD19-targeted CAR-T cell therapy, neurodegenerative-like movement disorders are characteristically associated with BCMA-targeted therapies, not CD19. We report a distinct case of persistent parkinsonism that became evident during recurrent neurological deterioration accompanied by a decline in ICE score in a patient treated with axicabtagene ciloleucel for relapsed diffuse large B cell lymphoma. Notably,\n                    <jats:sup>123<\/jats:sup>\n                    I-Ioflupane SPECT revealed reduced striatal dopamine transporter uptake, consistent with nigrostriatal dopaminergic dysfunction. This case expands the neurological spectrum of CD19 CAR-T cell therapy and suggests that persistent parkinsonism may occur in temporal association with ICANS. Clinicians should be aware that persistent movement disorders may complicate the course of CD19 CAR-T cell therapy, warranting comprehensive imaging evaluation in patients with atypical neurological recovery.\n                  <\/jats:p>","DOI":"10.1007\/s12185-026-04269-0","type":"journal-article","created":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T10:46:12Z","timestamp":1787654772000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Persistent parkinsonism with dopaminergic denervation following axicabtagene ciloleucel therapy for diffuse large B cell lymphoma: a case report"],"prefix":"10.1007","author":[{"given":"Wataru","family":"Kinoshita","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michiaki","family":"Sato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuya","family":"Kurihara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arika","family":"Shimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akira","family":"Honda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yosuke","family":"Masamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayaka","family":"Seki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meiko","family":"Maeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wataru","family":"Satake","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4034-2422","authenticated-orcid":false,"given":"Mineo","family":"Kurokawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,25]]},"reference":[{"key":"4269_CR1","doi-asserted-by":"publisher","unstructured":"Crump M, Neelapu SS, Farooq U, et al. Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study. Blood. 2017;130(16):1800\u20131808. Blood. 2018;131(5):587\u20138. https:\/\/doi.org\/10.1182\/blood-2017-11-817775","DOI":"10.1182\/blood-2017-11-817775"},{"issue":"26","key":"4269_CR2","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","volume":"377","author":"SS Neelapu","year":"2017","unstructured":"Neelapu SS, Locke FL, Bartlett NL, Lekakis LJ, Miklos DB, Jacobson CA, et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N Engl J Med. 2017;377(26):2531\u201344. https:\/\/doi.org\/10.1056\/NEJMoa1707447.","journal-title":"N Engl J Med"},{"issue":"10254","key":"4269_CR3","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1016\/s0140-6736(20)31366-0","volume":"396","author":"JS Abramson","year":"2020","unstructured":"Abramson JS, Palomba ML, Gordon LI, Lunning MA, Wang M, Arnason J, et al. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. Lancet. 2020;396(10254):839\u201352. https:\/\/doi.org\/10.1016\/s0140-6736(20)31366-0.","journal-title":"Lancet"},{"issue":"10","key":"4269_CR4","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1016\/s1470-2045(21)00375-2","volume":"22","author":"SJ Schuster","year":"2021","unstructured":"Schuster SJ, Tam CS, Borchmann P, Worel N, McGuirk JP, Holte H, et al. Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study. Lancet Oncol. 2021;22(10):1403\u201315. https:\/\/doi.org\/10.1016\/s1470-2045(21)00375-2.","journal-title":"Lancet Oncol"},{"issue":"7","key":"4269_CR5","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1056\/NEJMoa2116133","volume":"386","author":"FL Locke","year":"2022","unstructured":"Locke FL, Miklos DB, Jacobson CA, Perales MA, Kersten MJ, Oluwole OO, et al. Axicabtagene ciloleucel as second-line therapy for large B-cell lymphoma. N Engl J Med. 2022;386(7):640\u201354. https:\/\/doi.org\/10.1056\/NEJMoa2116133.","journal-title":"N Engl J Med"},{"issue":"4","key":"4269_CR6","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","volume":"25","author":"DW Lee","year":"2019","unstructured":"Lee DW, Santomasso BD, Locke FL, Ghobadi A, Turtle CJ, Brudno JN, et al. ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol Blood Marrow Transplant. 2019;25(4):625\u201338. https:\/\/doi.org\/10.1016\/j.bbmt.2018.12.758.","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1","key":"4269_CR7","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-024-01579-w","volume":"17","author":"P Sesques","year":"2024","unstructured":"Sesques P, Kirkwood AA, Kwon M, Rejeski K, Jain MD, Di Blasi R, et al. Novel prognostic scoring systems for severe CRS and ICANS after anti-CD19 CAR T cells in large B-cell lymphoma. J Hematol Oncol. 2024;17(1):61. https:\/\/doi.org\/10.1186\/s13045-024-01579-w.","journal-title":"J Hematol Oncol"},{"issue":"17","key":"4269_CR8","doi-asserted-by":"publisher","first-page":"3397","DOI":"10.1182\/bloodadvances.2020003885","volume":"5","author":"M Pennisi","year":"2021","unstructured":"Pennisi M, Sanchez-Escamilla M, Flynn JR, Shouval R, Alarcon Tomas A, Silverberg ML, et al. Modified EASIX predicts severe cytokine release syndrome and neurotoxicity after chimeric antigen receptor T cells. Blood Adv. 2021;5(17):3397\u2013406. https:\/\/doi.org\/10.1182\/bloodadvances.2020003885.","journal-title":"Blood Adv"},{"issue":"14","key":"4269_CR9","doi-asserted-by":"publisher","first-page":"2799","DOI":"10.1182\/bloodadvances.2021004575","volume":"5","author":"U Greenbaum","year":"2021","unstructured":"Greenbaum U, Strati P, Saliba RM, Torres J, Rondon G, Nieto Y, et al. CRP and ferritin in addition to the EASIX score predict CAR-T-related toxicity. Blood Adv. 2021;5(14):2799\u2013806. https:\/\/doi.org\/10.1182\/bloodadvances.2021004575.","journal-title":"Blood Adv"},{"issue":"12","key":"4269_CR10","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1007\/s40263-018-0582-9","volume":"32","author":"J Gust","year":"2018","unstructured":"Gust J, Taraseviciute A, Turtle CJ. Neurotoxicity associated with CD19-targeted CAR-T cell therapies. CNS Drugs. 2018;32(12):1091\u2013101. https:\/\/doi.org\/10.1007\/s40263-018-0582-9.","journal-title":"CNS Drugs"},{"issue":"21","key":"4269_CR11","doi-asserted-by":"publisher","first-page":"5501","DOI":"10.1182\/bloodadvances.2025017378","volume":"9","author":"E Galli","year":"2025","unstructured":"Galli E, Di Blasi R, Di Rocco A, Cristinelli C, Pansini I, Bommier C, et al. Routine prophylaxis with levetiracetam offers no benefit in CD19 CAR-T for LBCL: a multicenter propensity-matched study. Blood Adv. 2025;9(21):5501\u20139. https:\/\/doi.org\/10.1182\/bloodadvances.2025017378.","journal-title":"Blood Adv"},{"key":"4269_CR12","doi-asserted-by":"publisher","DOI":"10.3390\/ph17081025","author":"Z Guo","year":"2024","unstructured":"Guo Z, Ding Y, Wang M, Zhai Q, Liu J, Du Q. Comparing the differences in adverse events among chimeric antigen receptor T-cell therapies: a real-world pharmacovigilance study. Pharm (Basel). 2024. https:\/\/doi.org\/10.3390\/ph17081025.","journal-title":"Pharm (Basel)"},{"issue":"2","key":"4269_CR13","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1038\/s41408-022-00629-1","volume":"12","author":"AD Cohen","year":"2022","unstructured":"Cohen AD, Parekh S, Santomasso BD, G\u00e1llego P\u00e9rez-Larraya J, van de Donk N, Arnulf B, et al. Incidence and management of CAR-T neurotoxicity in patients with multiple myeloma treated with ciltacabtagene autoleucel in CARTITUDE studies. Blood Cancer J. 2022;12(2):32. https:\/\/doi.org\/10.1038\/s41408-022-00629-1.","journal-title":"Blood Cancer J"},{"issue":"12","key":"4269_CR14","doi-asserted-by":"publisher","first-page":"2099","DOI":"10.1038\/s41591-021-01564-7","volume":"27","author":"O Van Oekelen","year":"2021","unstructured":"Van Oekelen O, Aleman A, Upadhyaya B, Schnakenberg S, Madduri D, Gavane S, et al. Neurocognitive and hypokinetic movement disorder with features of parkinsonism after BCMA-targeting CAR-T cell therapy. Nat Med. 2021;27(12):2099\u2013103. https:\/\/doi.org\/10.1038\/s41591-021-01564-7.","journal-title":"Nat Med"},{"issue":"12","key":"4269_CR15","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.1002\/mdc3.14239","volume":"11","author":"S Schneider","year":"2024","unstructured":"Schneider S, Aamodt WW, Pruitt AA, Berger JR. Parkinsonism associated with anti-B-cell maturation antigen chimeric antigen receptor T-cell therapy. Mov Disord Clin Pract. 2024;11(12):1625\u20138. https:\/\/doi.org\/10.1002\/mdc3.14239.","journal-title":"Mov Disord Clin Pract"},{"key":"4269_CR16","doi-asserted-by":"publisher","DOI":"10.1002\/mdc3.70452","author":"JB Sanderson","year":"2025","unstructured":"Sanderson JB, Lin YH, Su K, Wang Y, Portuguese A, Gauthier J, et al. Treatment-emergent parkinsonism in four patients treated with chimeric antigen receptor T-cell therapy. Mov Disord Clin Pract. 2025. https:\/\/doi.org\/10.1002\/mdc3.70452.","journal-title":"Mov Disord Clin Pract"},{"key":"4269_CR17","doi-asserted-by":"publisher","first-page":"4144","DOI":"10.1182\/blood-2025-4144","volume":"146","author":"K Zhu","year":"2025","unstructured":"Zhu K, Singh R, Gerson J. Parkinsonism after treatment with anti-CD19 CAR-T: case report, institutional data review, and pharmacovigilance analysis of the FDA adverse event reporting system database. Blood. 2025;146:4144.","journal-title":"Blood"},{"issue":"10343","key":"4269_CR18","doi-asserted-by":"publisher","first-page":"2294","DOI":"10.1016\/s0140-6736(22)00662-6","volume":"399","author":"M Kamdar","year":"2022","unstructured":"Kamdar M, Solomon SR, Arnason J, Johnston PB, Glass B, Bachanova V, et al. Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial. Lancet. 2022;399(10343):2294\u2013308. https:\/\/doi.org\/10.1016\/s0140-6736(22)00662-6.","journal-title":"Lancet"},{"issue":"4","key":"4269_CR19","doi-asserted-by":"publisher","first-page":"e123","DOI":"10.1016\/j.bbmt.2018.12.756","volume":"25","author":"N Frey","year":"2019","unstructured":"Frey N, Porter D. Cytokine release syndrome with chimeric antigen receptor T cell therapy. Biol Blood Marrow Transplant. 2019;25(4):e123\u20137. https:\/\/doi.org\/10.1016\/j.bbmt.2018.12.756.","journal-title":"Biol Blood Marrow Transplant"},{"issue":"5","key":"4269_CR20","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1093\/brain\/awz053","volume":"142","author":"DB Rubin","year":"2019","unstructured":"Rubin DB, Danish HH, Ali AB, Li K, LaRose S, Monk AD, et al. Neurological toxicities associated with chimeric antigen receptor T-cell therapy. Brain. 2019;142(5):1334\u201348. https:\/\/doi.org\/10.1093\/brain\/awz053.","journal-title":"Brain"},{"issue":"35","key":"4269_CR21","doi-asserted-by":"publisher","first-page":"3978","DOI":"10.1200\/jco.21.01992","volume":"39","author":"BD Santomasso","year":"2021","unstructured":"Santomasso BD, Nastoupil LJ, Adkins S, Lacchetti C, Schneider BJ, Anadkat M, et al. Management of immune-related adverse events in patients treated with chimeric antigen receptor T-cell therapy: ASCO guideline. J Clin Oncol. 2021;39(35):3978\u201392. https:\/\/doi.org\/10.1200\/jco.21.01992.","journal-title":"J Clin Oncol"},{"key":"4269_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2025.578717","volume":"407","author":"M Wronski","year":"2025","unstructured":"Wronski M, Wesselingh R, Kazzi C, Seery N, Ko K, Li J, et al. Neurotoxicity associated with chimeric antigen receptor T-cell therapy. J Neuroimmunol. 2025;407:578717. https:\/\/doi.org\/10.1016\/j.jneuroim.2025.578717.","journal-title":"J Neuroimmunol"},{"issue":"12","key":"4269_CR23","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1158\/2159-8290.cd-17-0698","volume":"7","author":"J Gust","year":"2017","unstructured":"Gust J, Hay KA, Hanafi LA, Li D, Myerson D, Gonzalez-Cuyar LF, et al. Endothelial activation and blood-brain barrier disruption in neurotoxicity after adoptive immunotherapy with CD19 CAR-T cells. Cancer Discov. 2017;7(12):1404\u201319. https:\/\/doi.org\/10.1158\/2159-8290.cd-17-0698.","journal-title":"Cancer Discov"},{"issue":"8","key":"4269_CR24","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1158\/2159-8290.cd-17-1319","volume":"8","author":"BD Santomasso","year":"2018","unstructured":"Santomasso BD, Park JH, Salloum D, Riviere I, Flynn J, Mead E, et al. Clinical and biological correlates of neurotoxicity associated with CAR T-cell therapy in patients with B-cell acute lymphoblastic leukemia. Cancer Discov. 2018;8(8):958\u201371. https:\/\/doi.org\/10.1158\/2159-8290.cd-17-1319.","journal-title":"Cancer Discov"},{"issue":"7","key":"4269_CR25","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1038\/nri1130","volume":"3","author":"RM Ransohoff","year":"2003","unstructured":"Ransohoff RM, Kivis\u00e4kk P, Kidd G. Three or more routes for leukocyte migration into the central nervous system. Nat Rev Immunol. 2003;3(7):569\u201381. https:\/\/doi.org\/10.1038\/nri1130.","journal-title":"Nat Rev Immunol"},{"key":"4269_CR26","doi-asserted-by":"publisher","DOI":"10.3390\/ijms241612699","author":"S Brandl","year":"2023","unstructured":"Brandl S, Reindl M. Blood-brain barrier breakdown in neuroinflammation: current in vitro models. Int J Mol Sci. 2023. https:\/\/doi.org\/10.3390\/ijms241612699.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"4269_CR27","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.cell.2020.08.022","volume":"183","author":"KR Parker","year":"2020","unstructured":"Parker KR, Migliorini D, Perkey E, Yost KE, Bhaduri A, Bagga P, et al. Single-cell analyses identify brain mural cells expressing CD19 as potential off-tumor targets for CAR-T immunotherapies. Cell. 2020;183(1):126-42.e17. https:\/\/doi.org\/10.1016\/j.cell.2020.08.022.","journal-title":"Cell"},{"issue":"1","key":"4269_CR28","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-023-01486-5","volume":"8","author":"W Zhang","year":"2023","unstructured":"Zhang W, Xiao D, Mao Q, Xia H. Role of neuroinflammation in neurodegeneration development. Signal Transduct Target Ther. 2023;8(1):267. https:\/\/doi.org\/10.1038\/s41392-023-01486-5.","journal-title":"Signal Transduct Target Ther"},{"issue":"4","key":"4269_CR29","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1172\/jci58656","volume":"122","author":"E Czirr","year":"2012","unstructured":"Czirr E, Wyss-Coray T. The immunology of neurodegeneration. J Clin Invest. 2012;122(4):1156\u201363. https:\/\/doi.org\/10.1172\/jci58656.","journal-title":"J Clin Invest"},{"issue":"12","key":"4269_CR30","doi-asserted-by":"publisher","first-page":"1600","DOI":"10.1002\/mds.26431","volume":"30","author":"D Berg","year":"2015","unstructured":"Berg D, Postuma RB, Adler CH, Bloem BR, Chan P, Dubois B, et al. MDS research criteria for prodromal Parkinson\u2019s disease. Mov Disord. 2015;30(12):1600\u201311. https:\/\/doi.org\/10.1002\/mds.26431.","journal-title":"Mov Disord"},{"issue":"2","key":"4269_CR31","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/s0197-4580(02)00065-9","volume":"24","author":"H Braak","year":"2003","unstructured":"Braak H, Del Tredici K, R\u00fcb U, de Vos RA, Jansen Steur EN, Braak E. Staging of brain pathology related to sporadic Parkinson\u2019s disease. Neurobiol Aging. 2003;24(2):197\u2013211. https:\/\/doi.org\/10.1016\/s0197-4580(02)00065-9.","journal-title":"Neurobiol Aging"},{"issue":"4","key":"4269_CR32","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1016\/s1474-4422(09)70062-6","volume":"8","author":"EC Hirsch","year":"2009","unstructured":"Hirsch EC, Hunot S. Neuroinflammation in Parkinson\u2019s disease: a target for neuroprotection? Lancet Neurol. 2009;8(4):382\u201397. https:\/\/doi.org\/10.1016\/s1474-4422(09)70062-6.","journal-title":"Lancet Neurol"},{"issue":"8","key":"4269_CR33","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1038\/s43018-024-00764-7","volume":"5","author":"JM Vinnakota","year":"2024","unstructured":"Vinnakota JM, Biavasco F, Schwabenland M, Chhatbar C, Adams RC, Erny D, et al. Targeting TGF\u03b2-activated kinase-1 activation in microglia reduces CAR T immune effector cell-associated neurotoxicity syndrome. Nat Rev Cancer. 2024;5(8):1227\u201349. https:\/\/doi.org\/10.1038\/s43018-024-00764-7.","journal-title":"Nat Rev Cancer"},{"issue":"7","key":"4269_CR34","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1080\/1750743x.2025.2510893","volume":"17","author":"S Giesler","year":"2025","unstructured":"Giesler S, Biavasco F, Wertheimer T, Zeiser R, Vinnakota JM. Biology-driven therapies of CAR T immune effector cell-associated neurotoxicity syndrome. Immunotherapy. 2025;17(7):513\u201323. https:\/\/doi.org\/10.1080\/1750743x.2025.2510893.","journal-title":"Immunotherapy"},{"key":"4269_CR35","doi-asserted-by":"crossref","unstructured":"Brugger F, Erro R, Balint B, K\u00e4gi G, Barone P, Bhatia KP. Why is there motor deterioration in Parkinson\u2019s disease during systemic infections-a hypothetical view. NPJ Parkinsons Dis. United States2015. p. 15014.","DOI":"10.1038\/npjparkd.2015.14"},{"issue":"6","key":"4269_CR36","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0094944","volume":"9","author":"A Umemura","year":"2014","unstructured":"Umemura A, Oeda T, Tomita S, Hayashi R, Kohsaka M, Park K, et al. Delirium and high fever are associated with subacute motor deterioration in Parkinson disease: a nested case-control study. PLoS ONE. 2014;9(6):e94944. https:\/\/doi.org\/10.1371\/journal.pone.0094944.","journal-title":"PLoS ONE"},{"issue":"15","key":"4269_CR37","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.1212\/wnl.0000000000003810","volume":"88","author":"L Saari","year":"2017","unstructured":"Saari L, Kivinen K, Gardberg M, Joutsa J, Noponen T, Kaasinen V. Dopamine transporter imaging does not predict the number of nigral neurons in Parkinson disease. Neurology. 2017;88(15):1461\u20137. https:\/\/doi.org\/10.1212\/wnl.0000000000003810.","journal-title":"Neurology"},{"issue":"8","key":"4269_CR38","doi-asserted-by":"publisher","first-page":"1885","DOI":"10.1007\/s00259-020-04817-8","volume":"47","author":"S Morbelli","year":"2020","unstructured":"Morbelli S, Esposito G, Arbizu J, Barthel H, Boellaard R, Bohnen NI, et al. EANM practice guideline\/SNMMI procedure standard for dopaminergic imaging in Parkinsonian syndromes 1.0. Eur J Nucl Med Mol Imag. 2020;47(8):1885\u2013912. https:\/\/doi.org\/10.1007\/s00259-020-04817-8.","journal-title":"Eur J Nucl Med Mol Imag"},{"issue":"9996","key":"4269_CR39","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1016\/s0140-6736(14)61393-3","volume":"386","author":"LV Kalia","year":"2015","unstructured":"Kalia LV, Lang AE. Parkinson\u2019s disease. Lancet. 2015;386(9996):896\u2013912. https:\/\/doi.org\/10.1016\/s0140-6736(14)61393-3.","journal-title":"Lancet"},{"issue":"Pt 8","key":"4269_CR40","doi-asserted-by":"publisher","first-page":"2123","DOI":"10.1093\/brain\/awm142","volume":"130","author":"PA Kempster","year":"2007","unstructured":"Kempster PA, Williams DR, Selikhova M, Holton J, Revesz T, Lees AJ. Patterns of levodopa response in Parkinson\u2019s disease: a clinico-pathological study. Brain. 2007;130(Pt 8):2123\u20138. https:\/\/doi.org\/10.1093\/brain\/awm142.","journal-title":"Brain"},{"key":"4269_CR41","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2023.1293732","volume":"14","author":"M Tamura","year":"2023","unstructured":"Tamura M, Takeda T, Kitayama Y, Suichi T, Shibuya K, Harada-Kagitani S, et al. Neuropathological features of levodopa-responsive parkinsonism in multiple system atrophy: an autopsy case report and comparative neuropathological study. Front Neurol. 2023;14:1293732. https:\/\/doi.org\/10.3389\/fneur.2023.1293732.","journal-title":"Front Neurol"}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-026-04269-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12185-026-04269-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-026-04269-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T10:46:13Z","timestamp":1787654773000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12185-026-04269-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,25]]},"references-count":41,"alternative-id":["4269"],"URL":"https:\/\/doi.org\/10.1007\/s12185-026-04269-0","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"value":"0925-5710","type":"print"},{"value":"1865-3774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,25]]},"assertion":[{"value":"30 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 August 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 August 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 August 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Y.K. received honoraria from Chugai Pharmaceutical. A.S. received contract from Gilead Sciences, Kite. A.H. received honoraria from Chugai Pharmaceutical. Y.M. received honoraria from Chugai Pharmaceutical and payments for expert testimony from Abbvie, BeOne Medicines, and Janssen Pharmaceutical K.K. W.S. received grants from AMED and JSPS, honoraria from Chugai Pharmaceutical and supporting for attending meetings from The\u00a0Michael\u00a0J.\u00a0Fox\u00a0Foundation\u00a0for\u00a0Parkinson\u2019s\u00a0Research and is fiduciary role of Japanese Society of Neurology. M.K. received honoraria from Chugai Pharmaceutical Company and Gilead Sciences, Kite, and is an associate editor of International Journal of Hematology. The remaining authors declare that they have no conflict of interest.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}}]}}